OTLK · Outlook Therapeutics, Inc. · Executive Compensation
$0.52
-0.04 (-7.84%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because our cash and cash equivalents, together with $51.1 million of net proceeds from our August 2026 Offering, will not be adequate to fund our currently planned operations through at least the 12 months from the date of this Quarterly Report, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
Market Cap
$126.42M
Shares
243.45M
Volume · Oct 23
3.08M
Avg daily vol (3M)
12.5M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert C. Jahr | President and Chief Executive Officer | $1,291,757 |
| C. Russell Trenary III | Former President and Chief Executive Officer | $1,246,752 |
| Jeff Evanson | Former Chief Commercial Officer | $1,159,107 |
| Lawrence Kenyon | CEO | $476,170 |
| Lawrence A. Kenyon | Executive Vice President and Chief Financial Officer; Former Interim Chief Executive Officer | $476,170 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| C. Russell Trenary III | Former President and Chief Executive Officer | $6,377,953 |
| Jeff Evanson | Former Chief Commercial Officer | $768,029 |
| Lawrence A. Kenyon | Executive Vice President and Chief Financial Officer; Former Interim Chief Executive Officer | $634,597 |
| Lawrence Kenyon | CEO | $634,597 |
| Robert C. Jahr | President and Chief Executive Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| C. Russell Trenary III | President and Chief Executive Officer | $1,758,862 |
| Jeff Evanson | Chief Commercial Officer | $718,195 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Terry Dagnon | Chief Operations Officer | $1,433,955 |
| Jeff Evanson | Chief Commercial Officer | $1,408,961 |
| C. Russell Trenary III | President and Chief Executive Officer | $1,333,179 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| C. Russell Trenary III | President and Chief Executive Officer | $7,455,612 |
| Lawrence Kenyon | CFO | $2,669,214 |
| Lawrence A. Kenyon | Executive Vice President, Chief Financial Officer, Treasurer and Corporate Secretary | $2,669,214 |
| Jeff Evanson | Chief Commercial Officer | $300,000 |
| Terry Dagnon | Chief Operations Officer | $300,000 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lawrence A. Kenyon | Executive Vice President, Chief Financial Officer, Treasurer and Corporate Secretary | $1,184,334 |
| Lawrence Kenyon | CFO | $1,184,334 |
| Jeff Evanson | Chief Commercial Officer | $159,677 |
| Terry Dagnon | Chief Operations Officer | $159,677 |
| C. Russell Trenary III | President and Chief Executive Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Lawrence Kenyon | CEO | $1,863,901 |
| Lawrence A. Kenyon | Director, Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary | $1,863,901 |
| Kenneth M. Bahrt | Former Chief Medical Officer | $1,625,250 |
| Jeff Evanson | Chief Commercial Officer | — |
| Terry Dagnon | Chief Operating Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Lawrence Kenyon | CEO | $716,132 |
| Lawrence A. Kenyon | Director, Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary | $716,132 |
| Kenneth M. Bahrt | Former Chief Medical Officer | $429,082 |
| Stephen J. McAndrew | Former Senior Vice President, Business Strategy & Development | $326,071 |
| Terry Dagnon | Chief Operating Officer | — |
| Jeff Evanson | Chief Commercial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lawrence A. Kenyon | member of the Board of Directors | Resigned | 2026-08-27 |
| Kevin Lundquist | Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer | Appointed | 2026-08-27 |
| Dr. Julia Haller | Class II director of the Board | Resigned | 2026-03-11 |
| Jeff Evanson | Chief Commercial Officer | Terminated | 2025-09-05 |
| Robert Charles Jahr | Class III director | Appointed | 2025-07-01 |
| Lawrence Kenyon | Interim Chief Executive Officer | Resigned | 2025-07-01 |
| Robert Charles Jahr | President and Chief Executive Officer | Appointed | 2025-07-01 |
| Lawrence A. Kenyon | Class III director | Appointed | 2025-01-31 |
| Lawrence A. Kenyon | Class II director | Resigned | 2025-01-31 |
| Lawrence A. Kenyon | Interim Chief Executive Officer | Appointed | 2024-12-04 |
| C. Russell Trenary III | member of the Company’s Board of Directors | Resigned | 2024-12-04 |
| Julia A. Haller | Class II director | Appointed | 2022-08-15 |
Leadership
- Robert C. Jahr CEO, Board Member
- Robert Charles Jahr CEO, Board Member
- Faisal G. Sukhtian Chairman
- Kevin Lundquist CFO
- Lawrence Kenyon CFO, Board Member
- LawrenceA. Kenyon CFO
- Terry Dagnon COO
- Andong Huang Board Member
- Dr. Julia A. Haller Board Member
- Gerd Auffarth Board Member
- Julia A. Haller Board Member
- Julian Gangolli Board Member
- Kurt J. Hilzinger Board Member
- Lawrence A. Kenyon Board Member
- Yezan Haddadin Board Member
Key facts
CIK
1649989
CUSIP
69012T305
13F (30d)
16 filings
12 filers
Visit website
Investor relations